Combo Drug Commercial Potential May Be Lowered By D.C. Court Ruling
Executive Summary
A Washington, D.C. federal appeals court ruling could have a significant impact on pharmaceutical companies that are eying combination therapies as growth drivers
You may also be interested in...
Combo Rx Product Market Potential Is Enhanced By Single Copay – Analysts
Combination drug products may have more market potential due to their copay advantage, sellside research analysts suggested April 1 at an IIR conference in Philadelphia
Combo Rx Product Market Potential Is Enhanced By Single Copay – Analysts
Combination drug products may have more market potential due to their copay advantage, sellside research analysts suggested April 1 at an IIR conference in Philadelphia
Lilly Symbyax Combo Clears FDA; Price, Dose Will Help Distinguish Brand
Lilly's launch plans for the bipolar depression therapy Symbyax combine a value pricing model with a unique dosing combination